These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20570056)

  • 1. Entry of hepatitis B virus: mechanism and new therapeutic target.
    Xie Y; Zhai J; Deng Q; Tiollais P; Wang Y; Zhao M
    Pathol Biol (Paris); 2010 Aug; 58(4):301-7. PubMed ID: 20570056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of glycosaminoglycans for binding and infection of hepatitis B virus.
    Leistner CM; Gruen-Bernhard S; Glebe D
    Cell Microbiol; 2008 Jan; 10(1):122-33. PubMed ID: 18086046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies to inhibit entry of HBV and HDV into hepatocytes.
    Urban S; Bartenschlager R; Kubitz R; Zoulim F
    Gastroenterology; 2014 Jul; 147(1):48-64. PubMed ID: 24768844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein.
    Gripon P; Cannie I; Urban S
    J Virol; 2005 Feb; 79(3):1613-22. PubMed ID: 15650187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient infection of primary tupaia hepatocytes with purified human and woolly monkey hepatitis B virus.
    Köck J; Nassal M; MacNelly S; Baumert TF; Blum HE; von Weizsäcker F
    J Virol; 2001 Jun; 75(11):5084-9. PubMed ID: 11333889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein.
    Petersen J; Dandri M; Mier W; Lütgehetmann M; Volz T; von Weizsäcker F; Haberkorn U; Fischer L; Pollok JM; Erbes B; Seitz S; Urban S
    Nat Biotechnol; 2008 Mar; 26(3):335-41. PubMed ID: 18297057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetics of the bile acid transporter and hepatitis B virus receptor Na+/taurocholate cotransporting polypeptide (NTCP) in hepatocytes.
    König A; Döring B; Mohr C; Geipel A; Geyer J; Glebe D
    J Hepatol; 2014 Oct; 61(4):867-75. PubMed ID: 24845614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B virus (HBV) virion and covalently closed circular DNA formation in primary tupaia hepatocytes and human hepatoma cell lines upon HBV genome transduction with replication-defective adenovirus vectors.
    Ren S; Nassal M
    J Virol; 2001 Feb; 75(3):1104-16. PubMed ID: 11152483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of a hepatitis B and hepatitis delta virus receptor binding site.
    Engelke M; Mills K; Seitz S; Simon P; Gripon P; Schnölzer M; Urban S
    Hepatology; 2006 Apr; 43(4):750-60. PubMed ID: 16557545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B virus infection is dependent on cholesterol in the viral envelope.
    Bremer CM; Bung C; Kott N; Hardt M; Glebe D
    Cell Microbiol; 2009 Feb; 11(2):249-60. PubMed ID: 19016777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B virus mutations associated with fulminant hepatitis induce apoptosis in primary Tupaia hepatocytes.
    Baumert TF; Yang C; Schürmann P; Köck J; Ziegler C; Grüllich C; Nassal M; Liang TJ; Blum HE; von Weizsäcker F
    Hepatology; 2005 Feb; 41(2):247-56. PubMed ID: 15660384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes.
    Glebe D; Urban S; Knoop EV; Cag N; Krass P; Grün S; Bulavaite A; Sasnauskas K; Gerlich WH
    Gastroenterology; 2005 Jul; 129(1):234-45. PubMed ID: 16012950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient Inhibition of Hepatitis B Virus Infection by a preS1-binding Peptide.
    Ye X; Zhou M; He Y; Wan Y; Bai W; Tao S; Ren Y; Zhang X; Xu J; Liu J; Zhang J; Hu K; Xie Y
    Sci Rep; 2016 Jul; 6():29391. PubMed ID: 27384014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attachment sites and neutralising epitopes of hepatitis B virus.
    Glebe D
    Minerva Gastroenterol Dietol; 2006 Mar; 52(1):3-21. PubMed ID: 16554703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small animal model systems for studying hepatitis B virus replication and pathogenesis.
    Dandri M; Lutgehetmann M; Volz T; Petersen J
    Semin Liver Dis; 2006 May; 26(2):181-91. PubMed ID: 16673296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B virus infection of tupaia hepatocytes in vitro and in vivo.
    Walter E; Keist R; Niederöst B; Pult I; Blum HE
    Hepatology; 1996 Jul; 24(1):1-5. PubMed ID: 8707245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocyte polarization is essential for the productive entry of the hepatitis B virus.
    Schulze A; Mills K; Weiss TS; Urban S
    Hepatology; 2012 Feb; 55(2):373-83. PubMed ID: 21953491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myristoylated PreS1-domain of the hepatitis B virus L-protein mediates specific binding to differentiated hepatocytes.
    Meier A; Mehrle S; Weiss TS; Mier W; Urban S
    Hepatology; 2013 Jul; 58(1):31-42. PubMed ID: 23213046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP.
    Iwamoto M; Watashi K; Tsukuda S; Aly HH; Fukasawa M; Fujimoto A; Suzuki R; Aizaki H; Ito T; Koiwai O; Kusuhara H; Wakita T
    Biochem Biophys Res Commun; 2014 Jan; 443(3):808-13. PubMed ID: 24342612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of hepatocytes to investigate HDV infection: the HDV/HepaRG model.
    Sureau C
    Methods Mol Biol; 2010; 640():463-73. PubMed ID: 20645068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.